Illumina (NASDAQ:ILMN – Get Free Report) had its price target boosted by stock analysts at UBS Group from $133.00 to $145.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The firm presently has a “neutral” rating on the life sciences company’s stock. UBS Group’s price objective would indicate a potential downside of 4.50% from the stock’s previous close.
A number of other equities research analysts also recently weighed in on the company. Daiwa America raised Illumina to a “strong-buy” rating in a report on Friday, August 16th. Scotiabank decreased their price target on Illumina from $176.00 to $164.00 and set a “sector outperform” rating on the stock in a research note on Thursday, August 15th. Royal Bank of Canada increased their price objective on Illumina from $252.00 to $254.00 and gave the stock an “outperform” rating in a research note on Tuesday. Robert W. Baird boosted their target price on shares of Illumina from $119.00 to $124.00 and gave the company a “neutral” rating in a research note on Wednesday, August 7th. Finally, Argus upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $150.00 target price for the company in a research report on Wednesday, August 28th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, fourteen have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $162.18.
Read Our Latest Research Report on Illumina
Illumina Price Performance
Illumina (NASDAQ:ILMN – Get Free Report) last announced its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.26. The firm had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 6.36%. The business’s revenue for the quarter was down 3.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.33 EPS. Sell-side analysts predict that Illumina will post 3.62 earnings per share for the current year.
Institutional Trading of Illumina
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Envestnet Portfolio Solutions Inc. grew its position in shares of Illumina by 426.0% during the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 15,460 shares of the life sciences company’s stock worth $2,123,000 after buying an additional 12,521 shares during the period. Jupiter Asset Management Ltd. bought a new stake in shares of Illumina during the 1st quarter valued at $4,527,000. US Bancorp DE lifted its stake in shares of Illumina by 33.9% in the 1st quarter. US Bancorp DE now owns 31,600 shares of the life sciences company’s stock valued at $4,339,000 after purchasing an additional 8,001 shares during the period. Cetera Advisors LLC acquired a new position in shares of Illumina in the 1st quarter valued at $610,000. Finally, Weybosset Research & Management LLC grew its stake in shares of Illumina by 92.0% during the third quarter. Weybosset Research & Management LLC now owns 18,052 shares of the life sciences company’s stock worth $2,354,000 after purchasing an additional 8,650 shares during the period. 89.42% of the stock is owned by institutional investors.
Illumina Company Profile
Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Read More
- Five stocks we like better than Illumina
- 3 Small Caps With Big Return Potential
- What a Trump Win Looks Like for the Market Now and Into 2025
- What is the FTSE 100 index?
- Russell 2000 Surge Post-Election: How to Play the Small-Cap Pop
- How to Invest in the FAANG Stocks
- Macro Headwinds Send Microchip Technology Stock to the Buy Zone
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.